利拉鲁肽联合甘精胰岛素治疗2型糖尿病患者临床疗效
|
摘要
目的:分析2型糖尿病(T2DM)患者采取利拉鲁肽联合甘精胰岛素治疗的临床疗效。方法:选取本院于2016-02-2018-12期间收治的88例T2DM患者,随机分为两组,利拉鲁肽联合甘精胰岛素组作为研究组(n=46),单纯采用甘精胰岛素治疗组作为对照组(n=42),比较两组治疗后空腹血糖(FPG)、餐后2h血糖(2hPG)和糖化血红蛋白(HbAlc)水平变化,甘精胰岛素日用量、血糖达标时间及低血糖发生率。结果:与同组治疗前比较,两组患者治疗后FPG、2hPG、HbAlc水平均降低(P<0.01);研究组治疗后FPG、2hPG、HbAlc、甘精胰岛素日使用剂量均低于对照组,血糖达标时间短于对照组,且低血糖发生率低于对照组,差异均有统计学意义(P<0.01)。结论:利拉鲁肽联合甘精胰岛素联合治疗T2DM临床疗效显著,能改善血糖水平,减少胰岛素用量,缩短血糖达标时间以及降低不良反应发生率,值得临床推广应用。
Objective: To analyze the clinical efficacy of liraglutide combined with insulin glargine in patients with type 2 diabetes(T2DM). Method: Eighty-eight patients with T2DM admitted to our hospital from February 2016 to December 2018 were randomly divided into two groups. The liraglutide combined with insulin glargine group was used as the study group(n=46) and insulin glargine treatment group as the control group(n=42). The levels of fasting blood glucose(FPG), postprandial 2h blood glucose(2hPG), glycosylated hemoglobin(HbAlc), daily dose of insulin glargine, blood glucose compliance time and the rate of hypoglycemia were compared between the two groups. Results: The levels of FPG, 2hPG and HbAlc in the two groups after treatment were lower than those before treatment(P<0.01). The levels of FPG, 2hPG, HbAlc, the daily doses of insulin glargine in study group after treatment were lower than those of the control group, and the blood glucose compliance time was shorter than that of the control group, and also the incidence of adverse reactions was lower than that of the control group(P<0.01). Conclusion: The clinical efficacy of liraglutide combined with insulin glargine in patients with type 2 diabetes is significant. It can help improving blood sugar level, reducing insulin dosage, shortening blood glucose compliance time and reducing the incidence of adverse reactions. It is worthy of clinical application.
Objective: To analyze the clinical efficacy of liraglutide combined with insulin glargine in patients with type 2 diabetes(T2DM). Method: Eighty-eight patients with T2DM admitted to our hospital from February 2016 to December 2018 were randomly divided into two groups. The liraglutide combined with insulin glargine group was used as the study group(n=46) and insulin glargine treatment group as the control group(n=42). The levels of fasting blood glucose(FPG), postprandial 2h blood glucose(2hPG), glycosylated hemoglobin(HbAlc), daily dose of insulin glargine, blood glucose compliance time and the rate of hypoglycemia were compared between the two groups. Results: The levels of FPG, 2hPG and HbAlc in the two groups after treatment were lower than those before treatment(P<0.01). The levels of FPG, 2hPG, HbAlc, the daily doses of insulin glargine in study group after treatment were lower than those of the control group, and the blood glucose compliance time was shorter than that of the control group, and also the incidence of adverse reactions was lower than that of the control group(P<0.01). Conclusion: The clinical efficacy of liraglutide combined with insulin glargine in patients with type 2 diabetes is significant. It can help improving blood sugar level, reducing insulin dosage, shortening blood glucose compliance time and reducing the incidence of adverse reactions. It is worthy of clinical application.
引文
1 Wang L,Gao P,Zhang M,et al.Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J].JAMA,2017,317(24):2 515-2 523.
2 陈红霞,史婷婷,袁群,等.西格列汀与二甲双胍联用治疗老年2型糖尿病的疗治效观察[J].微循环学杂志,2019,29(1):18-22.
3 Sharma V,Pangtey GS,Gupta R,et al.Correlation of long-term glycemic control as measured by glycated hemoglobin with serum angiopoietin-like 6 protein levels in type 2 diabetes mellitus patients[J].Indian J Pharmacol,2017,49(3):250-253.
4 Kramer CK,Zinman B,Choi H,et al.Impact of the glucagon assay when assessing the effect of chronic liraglutide therapy on glucagon secretion[J].J Clin Endocrinol Metab,2017,102(8):2 729-2 733.
5 牛颜丽,吴国富,袁靖.胰岛素治疗的肥胖2型糖尿病患者加用利拉鲁肽的临床疗效研究[J].中国全科医学,2014,17(1):56-60.
6 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中国糖尿病杂志,2014,22(8):2-42.
7 中华医学会内分泌分会.中国成人住院患者高血糖管理目标专家共识[J].中华内分泌代谢杂志,2013,29(3):189-195.
8 Harris C,Forst T,Heise T,et al.Hypoglycemia risk related to double dose is markedly reduced with basal insulin peglispro versus insulin glargine in patients with type 2 diabetes mellitus in a randomized trial:IMAGINE 8[J].Diabetes Technol Ther,2017,19(8):463-470.
9 彭望英,况福连.胰岛素联合口服药物治疗初诊2型糖尿病疗效研究[J].江西医药,2015,50(3):244-246.
10 何慧,张韶君,杨艳兰.利拉鲁肽与胰岛素强化治疗对新发肥胖2型糖尿病患者临床疗效的比较[J].中国药物与临床,2019,19(1):51-53.
11 周瑞君.利拉鲁肽联合胰岛素治疗2型糖尿病过程中血糖变化及安全性分析[J].基层医学论坛,2019,23(14):1 944-1 945.
12 余淑芳.利拉鲁肽治疗血糖控制不佳的2型糖尿病患者的临床疗效及安全性研究[J].湖南师范大学学报(医学版),2019,16(2):57-60.
2 陈红霞,史婷婷,袁群,等.西格列汀与二甲双胍联用治疗老年2型糖尿病的疗治效观察[J].微循环学杂志,2019,29(1):18-22.
3 Sharma V,Pangtey GS,Gupta R,et al.Correlation of long-term glycemic control as measured by glycated hemoglobin with serum angiopoietin-like 6 protein levels in type 2 diabetes mellitus patients[J].Indian J Pharmacol,2017,49(3):250-253.
4 Kramer CK,Zinman B,Choi H,et al.Impact of the glucagon assay when assessing the effect of chronic liraglutide therapy on glucagon secretion[J].J Clin Endocrinol Metab,2017,102(8):2 729-2 733.
5 牛颜丽,吴国富,袁靖.胰岛素治疗的肥胖2型糖尿病患者加用利拉鲁肽的临床疗效研究[J].中国全科医学,2014,17(1):56-60.
6 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中国糖尿病杂志,2014,22(8):2-42.
7 中华医学会内分泌分会.中国成人住院患者高血糖管理目标专家共识[J].中华内分泌代谢杂志,2013,29(3):189-195.
8 Harris C,Forst T,Heise T,et al.Hypoglycemia risk related to double dose is markedly reduced with basal insulin peglispro versus insulin glargine in patients with type 2 diabetes mellitus in a randomized trial:IMAGINE 8[J].Diabetes Technol Ther,2017,19(8):463-470.
9 彭望英,况福连.胰岛素联合口服药物治疗初诊2型糖尿病疗效研究[J].江西医药,2015,50(3):244-246.
10 何慧,张韶君,杨艳兰.利拉鲁肽与胰岛素强化治疗对新发肥胖2型糖尿病患者临床疗效的比较[J].中国药物与临床,2019,19(1):51-53.
11 周瑞君.利拉鲁肽联合胰岛素治疗2型糖尿病过程中血糖变化及安全性分析[J].基层医学论坛,2019,23(14):1 944-1 945.
12 余淑芳.利拉鲁肽治疗血糖控制不佳的2型糖尿病患者的临床疗效及安全性研究[J].湖南师范大学学报(医学版),2019,16(2):57-60.